Fitch Upgrades Hikma Pharmaceuticals Plc’s Long-term Issuer Default Rating To ‘BBB’, Outlook Stable

By Ron Chen, Bureau Chief, Asia

Hikma Pharmaceuticals Plc  has announced that Fitch has upgraded its long-term issuer default rating and the senior unsecured rating on Hikma Finance USA LLC’s US$500 million notes to ‘BBB’ from ‘BBB-‘ with a stable outlook.

CFO of Hikma Khalid Nabilsi, said: “I am pleased that now both Fitch and S&P have upgraded Hikma to BBB, reinforcing our investment grade rating. These upgrades are a strong endorsement of our strategic direction, financial discipline, and operational resilience. They underscore Hikma’s solid market position across key geographies and reflect confidence in our ability to consistently deliver strong financial results, supported by our diversified business model, robust balance sheet, and prudent capital allocation.”